Stock Ratings / Health Care / OMER / financials

KRSA (33) DMRA (47) AAPG (57) KARD (61) ⌘ Pro Terminal →

Omeros Corporation (OMER) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$18.95 +5.98% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $19.12

Omeros Corporation (OMER) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $1.37B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $19.12 (+0.89%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.1% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-5.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for OMER)Realized 20D OHLCV Swing Band: ±10.5%

Deterministic 5-Pillar Attribution (46/100 Composite)

🔍 WHY OMER SCORES 46/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+15/20 pts (33% of score)

20D Institutional Volume Accumulation (±10.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+12/20 pts (26% of score)

FRED Regime × Technicals: 85% of 52W Range • RSI-14 at 53.6 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$19.83-18.3% Next Q

Q2 (-2Q)

Grade C-$16.20+2.3% Next Q

Q3 (-1Q)

Grade D$16.57+14.4% Next Q

Current

Grade D$18.95-6.1% Hist 90D α

Trajectory: C- (54) → D (46)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a OMER Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While OMER currently carries a cautious 46/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Big institutional funds and options desks are actively positioning on the bullish side.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($18.52) and Max Pain ($19.90) forces dealer call-delta covering toward $22.30.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $OMER• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “OMER Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 46%NO 54%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How OMER Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY24

Rev $4.00B

FY25

Rev $4.00B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$4.00B	52%	-3.1%	$0	-$116.2M	-45%
FY 2024	$4.00B	52%	-4.2%	$0	-$149.0M	-45%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring OMER)

✓Walkthrough of OMER's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

OMER // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +29.79%▲ ASCENDING CHANNEL

2026-10-30O $18.53H $19.01L $18.05C $18.95VOL 884.5K

RES: $20.49SUP: $16.90SMA50: $18.52SMA200: $13.49

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

OMER Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 OMER Butterfly Map → + Track OMER →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on OMER today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for OMER. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for OMER today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (OMER)

Health Care Rank #443 of 1016 ⚔️ KRSA vs OMER Full Matrix →

1. Head-to-Head Health Care Peer Comparison (OMER vs. KRSA, DMRA, AAPG, KARD)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Omeros Corporation (OMER) ranks #443 by composite RQD confidence (46/100, grade D) and #317 by equity capitalization ($1.37B). Within this direct 5-issuer industry benchmark cohort, OMER leads on earnings valuation at N/A trailing P/E, while KRSA leads on capital efficiency and profitability with -5.7% ROIC and — gross margin. KARD currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with OMER at 46/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
OMER ACTIVE Omeros Corporation	D	46/100	—	—	-35.0%	+5.98%	$1.37B	Benchmark Subject
KRSA Korsana Biosciences Inc.	E	33/100	—	—	-5.7%	+0.37%	$1.38B	/krsa-vs-omer →
DMRA Damora Therapeutics Inc.	D	47/100	—	—	-35.0%	+1.85%	$1.36B	/dmra-vs-omer →
AAPG Ascentage Pharma Group International American Depository Shares	D+	57/100	—	—	—	-0.70%	$1.39B	/aapg-vs-omer →
KARD Kardigan Inc.	C-	61/100	—	—	—	+4.22%	$1.34B	/kard-vs-omer →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001285819

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Omeros Corporation (OMER) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of $0, operating cash flow of -$116.1M, and free cash flow of -$116.2M (+22.0% YoY). On the balance sheet, OMER closed FY2025 with $325.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	$0	-$116.1M	-$116.2M	$325.6M	—
FY2024 (FY)	2024-12-31	$0	$0	-$148.8M	-$149.0M	$277.1M	—

3. OMER Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is OMER stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Omeros Corporation (NASDAQ: OMER) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $18.95 (+5.98% 1D, market cap $1.37B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, OMER ranks #443 in composite RQD confidence.

How does OMER compare to KRSA and DMRA in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), OMER carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, KRSA (Korsana Biosciences Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -5.7%, cap $1.38B) and DMRA (Damora Therapeutics Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $1.36B). Among the 5-stock peer group, OMER leads on earnings multiple (N/A) while KRSA leads on capital efficiency (-5.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for OMER?

Per OMER's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001285819), Omeros Corporation generated $0 in revenue, $0 in net income, and -$116.2M in free cash flow against $325.6M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is OMER trading relative to its 50-day, 200-day, and 52-week technical levels?

OMER last traded at $18.95 (+5.98% on volume of 3,627,968 shares), positioning the stock +2.32% above its 50-day simple moving average ($18.52) and +40.47% above its 200-day simple moving average ($13.49). Across its 52-week range of $6.24 to $21.24, OMER sits at the 84.7% percentile with a 14-day RSI of 53.6 (NEUTRAL RANGE) and an implied next-earnings move of ±10.5% ($16.96 to $20.94).